Affiliation:
1. the First Affiliated Hospital of Chongqing Medical University
2. Women and Children's Hospital of Chongqing Medical University, Chongqing Medical University
3. Chongqing General Hospital
Abstract
Abstract
Background
Many previous observational studies have shown that primary aldosteronism (PA) can increase the risk of cardiovascular diseases (CVDs), but the causal relationship is unclear.
Methods
We performed a bidirectional two-sample Mendelian randomization (MR) analysis to explore the causal association between PA and CVDs using summary statistics from the large publicly accessible genome-wide association study (GWAS) of PA (Ncases=1,724, Ncontrols=4,246) as well as six types of CVDs. Moreover, the inverse variance weighted (IVW) was used as the main method in MR analysis, and sensitivity analysis was further performed.
Results
Our results from the IVW analysis showed that genetically predicated PA conferred an increased risk of heart failure [odds ratio (OR) = 1.027, 95% confidence interval (CI): 1.013–1.041, p = 1.452×10− 4], atrial fibrillation (OR = 1.066, 95%CI: 1.051–1.082, p = 2.835×10− 17), hypertension (OR = 1.163, 95%CI: 1.105–1.223, p = 4.752×10− 9), coronary artery disease (OR = 1.032, 95%CI: 1.022–1.043, p = 1.664×10− 9), stroke (OR = 1.060, 95%CI: 1.044–1.075, p = 2.270×10− 15), myocardial infarction (OR = 1.020, 95%CI: 1.001–1.039, p = 0.044). However, with the exception of hypertension (OR = 3.316, 95%CI: 1.347–8.159, p = 0.009), CVDs leading to PA were not confirmed in reverse causality analysis. The sensitivity analysis showed the robustness of the results.
Conclusion
It is confirmed from the genetic level that there is a causal relationship between PA and CVDs and also confirmed that PA and hypertension are mutually causal. Our work highlights the necessity of routine screening, diagnosis and treatment of PA.
Publisher
Research Square Platform LLC
Reference41 articles.
1. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis;Monticone S;Lancet Diabetes Endocrinol,2018
2. Diagnosis and management of primary aldosteronism;Vilela LAP;Arch Endocrinol Metab,2017
3. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline;Funder JW;J Clin Endocrinol Metab,2016
4. Papadopoulou-Marketou N, Vaidya A, Dluhy R, Chrousos GP. Hyperaldosteronism. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2023. MDText.com, Inc.; 2000.
5. Pathogenesis of Primary Aldosteronism: Impact on Clinical Outcome;Santana LS;Front Endocrinol (Lausanne),2022